Status | Study |
Recruiting |
Study Name: CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Condition: Acute Myeloid Leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Date: 2016-03-31 Interventions: Biological: anti-CD7 CAR-pNK cells The allogeneic NK cells (NK-92 cell line for clinical use) are engine |
Active, not recruiting |
Study Name: Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Condition: Cutaneous T-cell Lymphoma T-Prolymphocytic Leukemia Date: 2015-07-29 Interventions: Drug: Romidepsin |
Recruiting |
Study Name: Registry of the German CLL Study Group Condition: CLL SLL HCL Richter´ Date: 2015-02-26 |
Recruiting |
Study Name: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Condition: Adult Acute Lymphoblastic Leukemia Adult Acute Myeloid Leukemia Date: 2010-11-29 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Active, not recruiting |
Study Name: Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Condition: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Aggres Date: 2010-10-28 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
Study Name: Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Condition: T-cell-prolymphocytic Leukemia Date: 2010-08-20 Interventions: Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab |
Withdrawn |
Study Name: Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Condition: Leukemia Acute Lymphocytic Leukemia Date: 2010-07-12 Interventions: Drug: Velcade IV Other Name: Bortezomib |
Active, not recruiting |
Study Name: Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Condition: Leukemia Date: 2010-03-25 Interventions: Drug: Nelarabine Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central cathet |
Recruiting |
Study Name: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Condition: B-Cell Prolymphocytic Leukemia Hypodiploidy Loss of Chromo Date: 2009-11-04 Interventions: Procedure: Allogeneic Bone Marrow Transplantation |
Completed |
Study Name: A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) Condition: Solid Tumors Chronic Lymphocytic Leukemia Date: 2008-09-05 Interventions: Drug: MK-4827 MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation |